Beijing Chenguang Tongchuang Pharmaceutical Research Institute is a newly established pharmaceutical research and development unit. It was invested and established by Chenguang Biotechnology Group Co., Ltd. (referred to as Chenguang Biotechnology, stock code 300138) and is engaged in the research and development of generic drugs and innovative drugs. Located in the headquarters base in the southwestern Fourth Ring Road of Beijing, the institute is currently in its initial stage. It has nearly 30 technical staff, including professionals in chemical synthesis, pharmaceutical formulation, pharmaceutical analysis, and pharmacology. The institute is equipped with various advanced instruments and equipment, including 14 HPLCs, GC, UV, oral solid preparation R&D equipment, and a pilot workshop for liquid preparations (including small injections, infusions, oral liquids, and lyophilized powder injections). The varieties developed by the institute serve both the pharmaceutical enterprises under Chenguang Biotechnology and can also be independently held. Upholding the group's core philosophy of "People and Enterprise Develop Together" and the mission of contributing to public health, the company and its employees are bound to achieve a brilliant future through collective efforts.